MAPK8 and central nervous system cancer: TNFRSF11A, also regarded as the receptor activator of NF-κB (RANK), can activate several pathways, such as NF-κB, JNK, ERK, p38, and Akt/PKB, and was reported to be a novel and frequent target for de novo methylation in gliomas [23].